enGene Holdings Inc. (NASDAQ:ENGN) Receives $33.67 Consensus PT from Brokerages

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have been given a consensus rating of “Buy” by the seven brokerages that are currently covering the firm, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued a report on the stock in the last year is $33.67.

Several research firms have commented on ENGN. Morgan Stanley restated an “overweight” rating and issued a $40.00 price objective on shares of enGene in a research report on Wednesday, September 11th. Oppenheimer reissued an “outperform” rating and issued a $30.00 price target on shares of enGene in a research report on Tuesday, September 24th.

Insider Activity at enGene

In other enGene news, major shareholder Growth Opportunities F. Forbion purchased 11,844 shares of the stock in a transaction on Monday, October 7th. The stock was bought at an average price of $6.55 per share, for a total transaction of $77,578.20. Following the acquisition, the insider now directly owns 2,469,833 shares of the company’s stock, valued at $16,177,406.15. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. In related news, major shareholder Growth Opportunities F. Forbion acquired 11,844 shares of enGene stock in a transaction on Monday, October 7th. The shares were bought at an average price of $6.55 per share, for a total transaction of $77,578.20. Following the completion of the purchase, the insider now directly owns 2,469,833 shares in the company, valued at $16,177,406.15. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Growth Opportunities F. Forbion acquired 5,997 shares of the company’s stock in a transaction dated Friday, October 4th. The shares were purchased at an average price of $6.54 per share, for a total transaction of $39,220.38. Following the purchase, the insider now directly owns 2,457,989 shares of the company’s stock, valued at approximately $16,075,248.06. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 420,965 shares of company stock valued at $2,651,103. 13.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On enGene

Institutional investors have recently made changes to their positions in the business. Logos Global Management LP increased its holdings in enGene by 50.0% in the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after buying an additional 400,000 shares during the last quarter. SR One Capital Management LP bought a new stake in shares of enGene in the 2nd quarter worth approximately $4,715,000. Janus Henderson Group PLC acquired a new position in enGene during the 1st quarter valued at approximately $17,095,000. Finally, Altitude Crest Partners Inc. acquired a new position in shares of enGene during the first quarter valued at $2,039,000. 64.16% of the stock is owned by institutional investors and hedge funds.

enGene Trading Up 9.0 %

NASDAQ ENGN opened at $9.83 on Thursday. The company has a fifty day simple moving average of $6.77 and a two-hundred day simple moving average of $9.63. enGene has a 12-month low of $4.42 and a 12-month high of $43.00. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09. The stock has a market cap of $434.15 million, a P/E ratio of -5.72 and a beta of -0.69.

enGene (NASDAQ:ENGN) last released its earnings results on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.05. On average, analysts forecast that enGene will post -1.56 earnings per share for the current year.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.